Next Article in Journal
Genome-Wide Identification of the Nramp Gene Family in Spirodela polyrhiza and Expression Analysis under Cadmium Stress
Next Article in Special Issue
Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights
Previous Article in Journal
Insights into the Role of the Discontinuous TM7 Helix of Human Ferroportin through the Prism of the Asp325 Residue
Previous Article in Special Issue
Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Département de Biologie Médicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco
Institute for Research on Cancer and Aging of Nice, Centre Antoine Lacassagne, CNRS UMR 7284 and IN-SERM U1081, Université Cote d’Azur, 06200 Nice, France
LIA ROPSE, Laboratoire International Associé Université Côte d’Azur—Centre Scientifique de Monaco, 98000 Monaco, Monaco
Nuclear Medicine Department, Grenoble-Alpes University Hospital, 38000 Grenoble, France
Laboratoire Radiopharmaceutiques Biocliniques, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, 38000 Grenoble, France
Centre Hospitalier Princesse Grace, Nuclear Medicine Department, 98000 Monaco, Monaco
Author to whom correspondence should be addressed.
Theses authors contributed equally to this work.
Academic Editor: Claudio Luchini
Int. J. Mol. Sci. 2021, 22(12), 6413;
Received: 30 April 2021 / Revised: 18 May 2021 / Accepted: 20 May 2021 / Published: 15 June 2021
(This article belongs to the Special Issue Pancreatic Ductal Adenocarcinoma: Precursors and Variants)
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly devastating disease associated with poor prognosis. The lack of accurate diagnostic tests and failure of conventional therapies contribute to this pejorative issue. Over the last decade, the advent of theranostics in nuclear medicine has opened great opportunities for the diagnosis and treatment of several solid tumors. Several radiotracers dedicated to PDAC imaging or internal vectorized radiotherapy have been developed and some of them are currently under clinical consideration. The functional information provided by Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) could indeed provide an additive diagnostic value and thus help in the selection of patients for targeted therapies. Moreover, the therapeutic potential of β-- and α-emitter-radiolabeled agents could also overcome the resistance to conventional therapies. This review summarizes the current knowledge concerning the recent developments in the nuclear medicine field for the management of PDAC patients. View Full-Text
Keywords: PDAC; nuclear medicine; molecular imaging; internal vectorized radiotherapy PDAC; nuclear medicine; molecular imaging; internal vectorized radiotherapy
Show Figures

Figure 1

MDPI and ACS Style

Montemagno, C.; Cassim, S.; De Leiris, N.; Durivault, J.; Faraggi, M.; Pagès, G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int. J. Mol. Sci. 2021, 22, 6413.

AMA Style

Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? International Journal of Molecular Sciences. 2021; 22(12):6413.

Chicago/Turabian Style

Montemagno, Christopher, Shamir Cassim, Nicolas De Leiris, Jérôme Durivault, Marc Faraggi, and Gilles Pagès. 2021. "Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?" International Journal of Molecular Sciences 22, no. 12: 6413.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop